Elderly patients with acute myeloid leukemia (AML) have a poor prognosis, and innovative maintenance therapy could improve their outcomes. Androgens, used in the treatment of aplastic anemia, have been reported to block proliferation of and initiate differentiation in AML cells. We report the results of a multicenter, phase III, randomized open-label trial exploring the benefit of adding androgens to maintenance therapy in patients 60 years of age or older.
Elderly patients with acute myeloid leukemia (AML) have a poor prognosis, and innovative maintenance therapy could improve their outcomes. Androgens, used in the treatment of aplastic anemia, have been reported to block proliferation of and initiate differentiation in AML cells. We report the results of a multicenter, phase III, randomized open-label trial exploring the benefit of adding androgens to maintenance therapy in patients 60 years of age or older.
Patients and Methods
A total of 330 patients with AML de novo or secondary to chemotherapy or radiotherapy were enrolled in the study. Induction therapy included idarubicin 8 mg/m 2 on days 1 to 5, cytarabine 100 mg/m 2 on days 1 to 7, and lomustine 200 mg/m 2 on day 1. Patients in complete remission or partial remission received six reinduction courses, alternating idarubicin 8 mg/m 2 on day 1, cytarabine 100 mg/m 2 on days 1 to 5, and a regimen of methotrexate and mercaptopurine. Patients were randomly assigned to receive norethandrolone 10 or 20 mg/day, according to body weight, or no norethandrolone for a 2-year maintenance therapy regimen. The primary end point was disease-free survival by intention to treat. Secondary end points were event-free survival, overall survival, and safety. This trial was registered at www.ClinicalTrials.gov identifier NCT00700544. Results Random assignment allotted 165 patients to each arm; arm A received norethandrolone, and arm B did not receive norethandrolone. Complete remission or partial remission was achieved in 247 patients (76%). The Schoenfeld time-dependent model showed that norethandrolone significantly improved survival for patients still in remission at 1 year after induction. In arms A and B, respectively, 5-year disease-free survival was 31.2% and 16.2%, event-free survival was 21.5% and 12.9%, and overall survival was 26.3% and 17.2%. Norethandrolone improved outcomes irrelevant to all prognosis factors. Only patients with baseline leukocytes . 30 3 10
INTRODUCTION
More than 70% of patients with acute myeloid leukemia (AML) are older than 60 years of age at the time of diagnosis. 1 The prognosis of these patients is particularly poor owing to a lower tolerance to intensive chemotherapies [1] [2] [3] and the presence of comorbidities. [4] [5] [6] Moreover, elderly patients frequently present with unfavorable prognostic features, such as poor-risk cytogenetics 7 and/or multidrug resistance phenotype. 8 Hence, in addition to higher treatment-related mortality, the complete remission (CR) rate achieved after induction chemotherapy is lower than that in young adults, and the remission duration is seldom longer than a year. Consequently, the overall survival (OS) of these patients rarely exceeds 15% beyond 5 years from diagnosis. [9] [10] [11] For this group of patients, improving the efficacy of postinduction chemotherapy and prolonging remission, without increasing treatment-related mortality, remains a challenge.
Androgens have been demonstrated to be useful in treating aplastic anemia since the late 1970s, 12-15 which led to testing these drugs in the treatment of AML with some success [16] [17] [18] in the 1980s. Most of these studies, however, were monocentric or had insufficient statistical power because of a low number of enrolled patients. In the 1990s, some in vitro studies showing that androgens were able to inhibit the proliferation of leukemic cell lines and induce differentiation revived interest in them. [19] [20] [21] [22] These observations suggested that these drugs, otherwise widely used and with limited toxicity, could prove valuable as maintenance therapy in elderly patients with AML. The French multicenter, open-label, randomized phase III trial reported here, performed by the Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang (GOELAMS), was conducted to determine whether low-dose norethandrolone given during the postinduction treatment phase would improve the outcome of elderly patients with newly diagnosed AML.
PATIENTS AND METHODS

Study Design and Patients
The LAM-SA2002 trial was an interventional, prospective, randomized, open-label phase III study carried out by 29 French centers of the GOELAMS (Appendix, online only). Eligibility criteria were limited to patients at least 60 years of age at the time of diagnosis, with untreated AML, either de novo or secondary to chemotherapy or radiation therapy, morphologically defined by the French-American-British classification, with a minimum of 20% bone marrow (BM) leukemic blasts. Additional eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) performance status # 2 and a minimal life expectancy of 1 month. Patients were ineligible if they had acute promyelocytic leukemia; a previous history of myelodysplastic syndrome or myeloproliferative disorder; CNS involvement or abnormal cardiac, liver, or renal function not attributable to leukemia; or a previous cerebral stroke or any coexisting medical or psychological condition that could interfere with study procedures. Male patients with breast cancer, prostate cancer, or elevated prostate-specific antigen were also excluded. All patients provided written informed consent before enrollment.
Chromosomal analysis of BM was performed at diagnosis. Data were reviewed by the GOELAMS cytogenetics committee. Cytogenetic analyses were performed according to international criteria: the International System for Human Cytogenetic Nomenclature. 23 Centrally reviewed cytogenetics was thus performed in 304 cases: high risk, n = 78; intermediate risk, n = 181; low risk, n = 14; and failure or partial failure, n = 31.
The final protocol (Data Supplement) was approved by the GOELAMS Acute Leukemia Committee and by the Institutional Review Board of Grenoble University Hospital and was registered at ClinicalTrials.gov identifier NCT00700544. The LAM-SA2002 study was conducted in accordance with the principles of the Declaration of Helsinki. The study was open to patient accrual in June 2002.
Randomization and Masking
Before initiation of the induction chemotherapy course, patients were registered and randomly assigned to receive low-dose norethandrolone or no norethandrolone at recovery from aplasia. Norethandrolone treatment was then sustained for all responding (CR or partial remission [PR]) randomly assigned patients. Random assignments at inclusion between arm A (receiving norethandrolone) and arm B (not receiving norethandrolone) were balanced, with a 1:1 ratio and stratified by center. Thirty days after the start of induction chemotherapy, a BM aspiration was performed. The inability to achieve at least a PR at this stage was considered a treatment failure and resulted in the removal of the patient from the study. The study was open label.
Treatment Plan
Induction therapy consisted of intravenous idarubicin 8 mg/m 2 on days 1 to 5, cytarabine 100 mg/m 2 on days 1 to 7 as a continuous infusion, and oral lomustine 200 mg/m 2 on day 1 (Fig 1) . If BM hypoplasia with less than 5% blasts was achieved by day 30, postinduction treatment was deferred and BM examination was repeated until the response was evaluable. Patients at least in PR received six reinduction cycles as postinduction treatment, one every 3 months. Between these cycles, and for a total of 2 years, maintenance treatment consisting of mercaptopurine and methotrexate was given. Specific dose modifications of the maintenance treatment were allowed.
Patients belonging to arm A started low-dose norethandrolone after recovery from induction-related aplasia. Norethandrolone was given orally at 20 mg/d (or 10 mg/d if body weight was below 60 kg), for a total duration of 2 years. Patients assigned to arm B received no additional treatment. Evaluation of the response was performed by microscopic examination of BM smears by morphologists blinded to the treatment arm. CR was defined as cellular BM with less than 5% blasts, no Auer rods, no evidence of extramedullary leukemia, and peripheral neutrophil and platelet counts of at least 1.0 3 10 9 /L and 100 3 10 9 /L, respectively. PR was defined as BM blasts between 5% and 15% with normal trilineage hematopoiesis, regardless of absolute neutrophil and platelet counts. Induction failure was defined as either the presence of peripheral blood blasts without myelemia, BM blasts . 15%, or BM aplasia for more than 60 days. Induction-related death was defined as death occurring before hematologic recovery from toxic and infectious causes. Relapse was defined as recurrence of leukemia after initial CR. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria handbook (version 2.0). All data forms were entered by staff members of each GOELAMS center and centrally reviewed. Members of the GOELAMS Data Monitoring Committee visited all participating centers to verify compliance with European regulations and protocol requirements.
Sample Size Calculation and Statistical Analyses
The primary objective of the study was to determine whether adding low-dose norethandrolone to postinduction chemotherapy could improve disease-free survival (DFS) in patients 60 years of age or older with newly diagnosed AML. Secondary objectives were to determine whether the addition of norethandrolone could also improve the event-free survival (EFS) and OS and reduce relapse incidence without increasing treatmentrelated toxicity. Three hundred thirty patients were planned to be enrolled over a 2-year period. This was based on the fact that, with an expected 60% rate of CR plus PR, a two-sided log-rank test with an overall sample size of 304 patients (152 patients per group) would achieve 80% power at a .05 significance level to detect a difference of 16% in terms of DFS between arm A (31%) and arm B (15%) at 36 months.
The database was frozen on September 2012. All analyses were conducted according to the intention-to-treat principle. DFS was measured from the date of the first CR to the date of relapse or death from any cause, whichever came first, or date of the last follow-up report. OS was defined as the time interval from randomization until death or last followup report, whichever came first. EFS was measured from the date of randomization to the date of failure to achieve remission, death, or relapse, whichever came first, or date of the last follow-up report. Categorical data were expressed as percentages and compared using x 2 tests or Fisher exact tests when appropriate. Continuous data were expressed as median (interquartile range) and compared using Wilcoxon or Mann-Whitney tests when appropriate. Censored data were compared using two-tailed log-rank tests and modeled using Cox regression models in the absence of competitive events. Proportional hazards assumptions were tested using scaled Schoenfeld residuals analyses. In case of departure from the proportional hazards assumption, time-dependent covariates were considered. The significance level was set at .05 for all the analyses. Stata 13.01 software (STATA, College Station, TX) was used for the statistical analyses, and PASS software (NCSS, Kaysville, UT) was used for sample size calculation.
Multivariable analyses adjusted to norethandrolone considered sex, age, ECOG performance status, peripheral blasts, French-AmericanBritish classification, cytogenetics, and WBC counts. For the latter, the 30 3 10 9 /L threshold planned in the protocol was used. Table 1 . The two arms were well balanced for all parameters.
RESULTS
Between
The overall response (CR plus PR) was achieved for 247 patients (76%). Two hundred thirty patients achieved CR (70.7%). Among the 17 patients in PR at the end of induction (arm A, n = 9; arm B, n = 8), nine finally reached CR (arm A, n = 6; arm B, n = 3). Treatment failure occurred for 26 patients (8%). Fifty-two patients (16%) died during the induction phase, of whom 23 died as a result of sepsis, five died as a result of multiorgan failure, four died as a result of cardiac injury, five died as a result of pneumonia, five died as a result of hemorrhage, four died as a result of acute respiratory distress syndrome, three died as a result of stroke, one died as a result of pulmonary embolism, and two died as a result of an unknown cause. In the subgroup of 78 patients with unfavorable cytogenetics, the CR rate was 59% and the PR rate was 6%; 19% experienced treatment failure, and early deaths were observed for 15%.
At the time of data analysis, median follow-up from the start of the induction chemotherapy was 1.2 years (first quartile, 0.36 years; third quartile, 3.5 years) for the overall group and 4.6 years (first quartile, 4.2 years; third quartile, 5.4 years) for patients alive at last report. Among the 230 patients who achieved CR (arm A, n = 111; arm B, n = 119), the five-year DFS was 31.2% (95% CI, 22.8% to 40.0%) in arm A versus 16.2% (95% CI, 10.2% to 23.5%) in arm B (Fig 2A) . One hundred forty-six patients relapsed (arm A, Table 2 . No differences between arm A and B were noted for rehospitalizations, the need for transfusions, or grade 3 and 4 toxicities. The incidence of secondary cancer was similar in both arms (arm A, n = 11; Arm B, n = 15), and specifically, there was no prostate cancer.
Multivariable analyses identified interactions between high a WBC count at diagnosis (ie, $ 30 3 10 9 /L) and postinduction treatment with norethandrolone for DFS and EFS (P = .05 and P = .037, respectively). In arms A and B, 117 patients (72%) and 127 patients (78%), respectively, had WBC counts , 30 3 10 9 /L. In this population, DFS and EFS were significantly better after the addition of androgen (Figs 3A and 3C), whereas there was no difference between arms in patients with a WBC count . 30 3 10 9 /L (Figs 3B and 3D) Time ( 
DISCUSSION
The present phase III randomized clinical trial shows that androgens added to postremission therapy improved the outcome in elderly patients with AML. In choosing to add androgens to postremission therapy, we expected to improve DFS, which was achieved, yet a beneficial effect was finally observed for EFS and OS. This beneficial effect was intriguingly time dependent and became significant only among patients who had failed to relapse during the first year of therapy. For this reason, an extended Cox model considering timedependent covariables was applied to compare treatment arms in patients' subgroups. This strategy allowed identification of diagnostic hyperleukocytosis as an additional prognostic factor in this setting. Indeed, benefit derived from the addition of norethandrolone as maintenance therapy was observed in all patients except those with a WBC count . 30 3 10 9 /L at diagnosis. Of note, even patients with poor-risk cytogenetics benefited from the addition of norethandrolone.
Another positive result of this trial was the higher-thanexpected rate of CR. On the basis of previous results from our group, 24 we had planned on 60% PR plus CR, whereas the observed rate was 76%. This was not linked to a different selection of patients or to different chemotherapy, but could be related to general recommendations for supportive care.
Moreover, there were no differences in toxicity between the two treatment arms and, notably, there was a similar rate of secondary cancers in this elderly population. The impact of molecular markers on AML prognosis was barely beginning to be comprehended at the time this clinical trial was launched and throughout the trial. No samples were specifically collected for such a posteriori studies; therefore, we cannot rule out a potential interaction between the effect of low-dose norethandrolone and molecular anomalies.
Little is known about the expected benefit of prolonged maintenance therapy in elderly patients with AML. Yet, in the study by Büchner et al, 25 3 years of a rather light maintenance therapy (ie, sequential high-dose cytosine arabinoside and mitoxantrone) significantly improved DFS in poor-prognosis patients with AML, including, among other criteria, patients older than 60 years of age. Similarly, but more specifically, in elderly patients with AML, Löwenberg et al 26 showed that subcutaneous low-dose cytarabine every 6 weeks prolonged DFS. A combination of low-dose chemotherapy and differentiating agents also proved efficient in poorrisk patients with AML in the Italian trial reported by Ferrero et al. 27 Here, along the same lines, we combined long-term chemotherapy and the constant addition of an agent shown to have some effect on the blockade of leukemic cell proliferation and/or their differentiation.
Indeed, one of the hypotheses of the positive effect of norethandrolone may lay in its activity on telomerase. Clonal myeloid disorders, such as aplastic anemia, myelodysplasia, and AML, share anomalies of the TERC/TERT partners of telomerase activity. 28 Shorter telomeres are present in the clonal cells of these disorders, as well as in other malignancies where mutation of the telomerase complex parallels genetic instability. In aplastic anemia, both in vitro and in vivo, androgens have been reported to increase telomerase activity and improve hematopoiesis. In the study by Ziegler et al, 29 restoration of hematopoiesis in aplastic anemia was shown to correlate with an increase in telomere length in all hematopoietic lineages. In a different perspective, sex steroids have been shown to influence the proliferation of myeloid cells, 21, 22 suggesting a possible direct interaction of androgens. In the MILE study (data courtesy of Torsten Haferlach, Munich Leukemia Laboratory), transcripts of the androgen receptor (Entrez accession No. 367 on Xq12), tested with four probe sets, were significantly more frequent in AML cells than in nonleukemic samples 30 (x 2 , 0.003 for three probe sets).
Several possibilities may thus explain the efficacy of norethandrolone in elderly patients with AML. Because androgen supplementation was initiated when the tumoral mass was decreased, it is possible that norethandrolone decreased the proliferation of remaining blast cells and/or their genetic instability in restoring proper telomere length. In addition, as in aplastic anemia, a beneficial effect could be exerted by androgens on normal hematopoietic cells recovering after the end of the postinduction aplastic phase. The long-term effect of norethandrolone, significant after 1 year of persistent CR, is consistent with these hypotheses. The fact that patients with higher blast counts at diagnosis do not benefit from this schedule moreover favors a beneficial effect on normal hematopoiesis, especially in an elderly population where telomere length is naturally decreased. This also suggests the absence of a direct effect of androgens on the killing of tumor cells, consistent with the time-dependence of their beneficial effect. A significant difference between the two treatment arms was clearly only seen after 1 year, implying that androgens prefer to act by favoring hematopoietic and hence immunologic reconstitution than by controlling early relapses. Indeed, such indirect effects of androgens could target the hematopoietic niche, the specific microenvironment of leukemic cells, or the immune system because all these elements have been shown to respond to gonadal hormones in numerous situations. It may thus be hypothesized that long-term restoration of a balance controlling residual leukemic cells would be responsible for the observed positive effect of androgen supplementation. These hypotheses would need to be tested in a future new prospective trial with norethandrolone or other more widely accessible androgens, together with an exploration of the cytogenetic/ molecular subgroups of patients most likely to benefit from such an addition to therapy. Globally, however, these data suggest that for the non-negligible population of elderly patients with AML with a WBC count , 30 3 10 9 /L at diagnosis, the addition of androgens could become a valid cost-effective maintenance therapy.
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